160 related articles for article (PubMed ID: 22699529)
1. Standardized added metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases.
Mertens J; Dobbeleir A; Ham H; D'Asseler Y; Goethals I; Van de Wiele C
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1441-8. PubMed ID: 22699529
[TBL] [Abstract][Full Text] [Related]
2. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
[TBL] [Abstract][Full Text] [Related]
3. Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography.
Degirmenci B; Wilson D; Laymon CM; Becker C; Mason NS; Bencherif B; Agarwal A; Luketich J; Landreneau R; Avril N
Nucl Med Commun; 2008 Jul; 29(7):614-22. PubMed ID: 18528183
[TBL] [Abstract][Full Text] [Related]
4. Standardized Added Metabolic Activity Predicts Survival After Intra-arterial Resin-Based 90Y Radioembolization Therapy in Unresectable Chemorefractory Metastatic Colorectal Cancer to the Liver.
Edalat F; Camacho JC; Kokabi N; Kendi AT; Galt JR; Kim HS
Clin Nucl Med; 2016 Feb; 41(2):e76-81. PubMed ID: 26447380
[TBL] [Abstract][Full Text] [Related]
5. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures.
Makris NE; Huisman MC; Kinahan PE; Lammertsma AA; Boellaard R
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1507-15. PubMed ID: 23754762
[TBL] [Abstract][Full Text] [Related]
7. Comparative assessment of methods for estimating tumor volume and standardized uptake value in (18)F-FDG PET.
Tylski P; Stute S; Grotus N; Doyeux K; Hapdey S; Gardin I; Vanderlinden B; Buvat I
J Nucl Med; 2010 Feb; 51(2):268-76. PubMed ID: 20080896
[TBL] [Abstract][Full Text] [Related]
8. Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer.
Heijmen L; de Geus-Oei LF; de Wilt JH; Visvikis D; Hatt M; Visser EP; Bussink J; Punt CJ; Oyen WJ; van Laarhoven HW
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1858-67. PubMed ID: 22945372
[TBL] [Abstract][Full Text] [Related]
9. Prediction of response to neoadjuvant radiotherapy in patients with locally advanced rectal cancer by means of sequential 18FDG-PET.
Everaert H; Hoorens A; Vanhove C; Sermeus A; Ceulemans G; Engels B; Vermeersch M; Verellen D; Urbain D; Storme G; De Ridder M
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):91-6. PubMed ID: 20605358
[TBL] [Abstract][Full Text] [Related]
10. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases.
Stinauer MA; Diot Q; Westerly DC; Schefter TE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e613-8. PubMed ID: 22494588
[TBL] [Abstract][Full Text] [Related]
11. Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy.
Maisonobe JA; Garcia CA; Necib H; Vanderlinden B; Hendlisz A; Flamen P; Buvat I
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):166-74. PubMed ID: 23151911
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?
Kendi AT; Corey A; Magliocca KR; Nickleach DC; Galt J; Switchenko JM; El-Deiry MW; Wadsworth JT; Hudgins PA; Saba NF; Schuster DM
Eur J Radiol; 2015 Jun; 84(6):1171-6. PubMed ID: 25816993
[TBL] [Abstract][Full Text] [Related]
13. Effects of reusing baseline volumes of interest by applying (non-)rigid image registration on positron emission tomography response assessments.
van Velden FH; Nissen IA; Hayes W; Velasquez LM; Hoekstra OS; Boellaard R
PLoS One; 2014; 9(1):e87167. PubMed ID: 24489860
[TBL] [Abstract][Full Text] [Related]
14. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer.
Oh D; Lee JE; Huh SJ; Park W; Nam H; Choi JY; Kim BT
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):549-54. PubMed ID: 24074928
[TBL] [Abstract][Full Text] [Related]
16. Quantitative p retreatment VOI analysis of liver metastases. (99m)Tc-MAA SPECT/CT and FDG PET/CT in relation with treatment response to SIRT.
Van de Wiele C; Stellamans K; Brugman E; Mees G; De Spiegeleer B; D'Asseler Y; Beels L; Maes A
Nuklearmedizin; 2013; 52(1):21-7. PubMed ID: 23358716
[TBL] [Abstract][Full Text] [Related]
17. Do 18F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status?
Kendi AT; Magliocca K; Corey A; Nickleach DC; Galt J; Higgins K; Beitler JJ; El-Deiry MW; Wadsworth JT; Hudgins PA; Saba NF; Schuster DM
Clin Nucl Med; 2015 Mar; 40(3):e196-200. PubMed ID: 25608156
[TBL] [Abstract][Full Text] [Related]
18. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
